Literature DB >> 27272787

HOXB7 Expression is a Novel Biomarker for Long-term Prognosis After Resection of Hepatocellular Carcinoma.

Hisateru Komatsu1, Tomohiro Iguchi2, Takaaki Masuda2, Masami Ueda1, Shinya Kidogami1, Yushi Ogawa2, Sho Nambara2, Kuniaki Sato2, Quingjang Hu2, Tomoko Saito2, Hidenari Hirata2, Shotaro Sakimura2, Ryutaro Uchi2, Naoki Hayashi2, Shuhei Ito2, Hidetoshi Eguchi3, Keishi Sugimachi2, Hidetoshi Eguchi3, Yuichiro Doki3, Masaki Mori3, Koshi Mimori4.   

Abstract

BACKGROUND/AIM: Homeobox B7 (HOXB7) gene is involved in various cellular functions. We investigated the clinical significance of HOXB7 expression in hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: HOXB7 mRNA expression in 103 HCC samples and 58 matched non-cancerous liver tissues were examined by quantitative real-time polymerase chain reaction (qRT-PCR). HOXB7 protein expression was also examined by immunohistochemistry. Gene set enrichment analysis (GSEA) was performed using a public dataset.
RESULTS: HOXB7 expression was significantly higher in HCC tissues than in liver parenchyma. Ten-year overall survival (OS) and 5-year recurrence-free survival (RFS) of cases with higher HOXB7 expression were significantly poorer than those with lower HOXB7 expression. HOXB7 expression was significantly associated with larger tumor size and higher rate of biliary invasion and constituted an independent prognostic factor for OS by multivariate analysis. These results were supported by GSEA.
CONCLUSION: HOXB7 expression in HCC could be a novel biomarker for long-term prognosis after tumor resection. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  HOXB7; hepatocellular carcinoma; prognostic biomarker

Mesh:

Substances:

Year:  2016        PMID: 27272787

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  The prognostic value of homeobox B7 expression in patients with hepatocellular carcinoma.

Authors:  Yarong Guo; Xiaojiang Qin; Bao Chai; Junmei Jia; Jiahong Yi; Kang Wang; Xiaomin Hou
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

2.  HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.

Authors:  Wei-Min Wang; Yang Xu; Yao-Hui Wang; Hai-Xiang Sun; Yun-Fan Sun; Yi-Feng He; Qing-Feng Zhu; Bo Hu; Xin Zhang; Jing-Lin Xia; Shuang-Jian Qiu; Jian Zhou; Xin-Rong Yang; Jia Fan
Journal:  Oncotarget       Date:  2017-07-18

3.  HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.

Authors:  Hong-Bo Huan; Da-Peng Yang; Xu-Dong Wen; Xue-Jiao Chen; Liang Zhang; Li-Li Wu; Ping Bie; Feng Xia
Journal:  J Exp Clin Cancer Res       Date:  2017-06-24

4.  Downregulation of Homeobox B7 Inhibits the Tumorigenesis and Progression of Osteosarcoma.

Authors:  Lei Yang; Fei Xie; Shuangqing Li
Journal:  Oncol Res       Date:  2016-11-08       Impact factor: 5.574

5.  DeepVISP: Deep Learning for Virus Site Integration Prediction and Motif Discovery.

Authors:  Haodong Xu; Peilin Jia; Zhongming Zhao
Journal:  Adv Sci (Weinh)       Date:  2021-03-08       Impact factor: 16.806

Review 6.  Homeobox Genes and Hepatocellular Carcinoma.

Authors:  Kwei-Yan Liu; Li-Ting Wang; Shih-Hsien Hsu; Shen-Nien Wang
Journal:  Cancers (Basel)       Date:  2019-05-03       Impact factor: 6.639

7.  Upregulated expression of HOXB7 in intrahepatic cholangiocarcinoma is associated with tumor cell metastasis and poor prognosis.

Authors:  Longfei Dai; Wendi Hu; Zhenjie Yang; Diyu Chen; Bin He; Yunhao Chen; Lin Zhou; Haiyang Xie; Jian Wu; Shusen Zheng
Journal:  Lab Invest       Date:  2019-01-21       Impact factor: 5.662

8.  HOXB7 acts as an oncogenic biomarker in head and neck squamous cell carcinoma.

Authors:  Xiang Wu; Jin Li; Tingyuan Yan; Xueping Ke; Xin Li; Yumin Zhu; Jianrong Yang; Zhongwu Li
Journal:  Cancer Cell Int       Date:  2021-07-24       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.